Home > COVID-19 Update: Dynavax Increases by 26% – Here’s Where to Buy It

COVID-19 Update: Dynavax Increases by 26% – Here’s Where to Buy It

Dynavax Technologies reports pivotal trial results that boosted its share price by 26%. The company developed an adjuvant to make a COVID-19 vaccine more effective.  

We are nowhere near the end of the pandemic. Yet, the good news is that many companies continue their R&D research on potential COVID-19 vaccines. Yesterday, Dynavax and its collaboration partner released positive trial results that used a booster to make the vaccine more effective.

Let’s find out more about Dynavax and why this news made investors push its stock 26.6% higher yesterday and over 30% in the past five days.

How & Where to Buy Dynavax Technologies Stock Online

Dynavax Technologies (NASDAQ: DVAX) and its collaboration partner, Clover Biopharmaceuticals, can be bought via online brokers. If you want to invest in these stocks, all you need to do is to choose a brokerage platform that provides access to Nasdaq stocks and create an account. Our top picks are:


eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.

Register with eToro instantly


Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.

Register with Webull instantly

What Is Dynavax Technologies?

Dynavax Technologies specialises in developing vaccines by using innovative technologies. One example is the HEPLISAV-B, a vaccine for Hepatitis B, which is also the main revenue source for the company.

Should I Buy Dynavax Technologies Today?

Dynavax Technologies partnered with Clover Biopharmaceuticals to develop a more effective COVID-19 vaccine. Yesterday, DVAX reported that their protein-based vaccine candidate, known as SCB-2019, was proved effective following a clinical trial that included more than 30,000 participants. The new vaccine has 100% efficacy against severe COVID-19 cases and 84% efficacy against moderate-to-severe cases caused by any strain.

Given the increasing concerns over the new variants, including Delta, investors embraced the news with optimism. The share price surged following this news; yet, it may be a long way until the vaccine is ready for administration at a global level. 

Dynavax Technologies Price Prediction 2021

Currently trading at $18.79, analysts expect the stock to reach a high target price of $23 in the next 12 months. The bearish scenario shows a minimum of $18.

Trade/invest in stocks with just $50
Invest for dividends and get payout on stocks on Ex-Dividend day
Over 11 payment methods, including PayPal
Open my Account

We use cookies to personalise content & ads, provide social media features and offer you a better experience. By continuing to browse the site or clicking "OK, Thanks" you are consenting to the use of cookies on this website.